Business Parks & Science Centres

 
 
 

Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px
Collaboration › Details

Bayer–Cyclica: drug discovery services, 201811– collab using cloud-based proteome screening platform for small molecule drug development

 

Period Period 2018-11-26
Organisations Partner, 1st Bayer AG
  Group Bayer (Group)
  Partner, 2nd Cyclica Inc.
Products Product Ligand Express® cloud-based proteome screening platform
  Product 2 drug discovery
     

Cyclica Inc.. (11/26/18). "Press Release: Cyclica Drives Drug Discovery through AI-Augmented Integrated Network of Cloud-Based Technologies together with Bayer". Toronto.

Cyclica (www.cyclicarx.com), a Bayer G4A company is pleased to announce a collaboration with Bayer to advance drug discovery programs by gaining insights into the polypharmacological profiles of small molecules, while further evolving Cyclica’s integrated network of enabling technologies.

Through a multi-phase collaboration, Cyclica will provide its cloud-based proteome screening Ligand Express® platform to investigate the off-target profiles of small molecules, apply its novel and proprietary advanced AI technology to create state-of-the-art predictive models for pharmacokinetic properties, and leverage its first-in-class Differential Drug Design (DDD) technology for multi-targeted drug design.

Naheed Kurji, President and CEO of Cyclica said, “We are thrilled to have the opportunity to work closely with the world-leading scientists at Bayer to advance drug discovery through a holistic set of AI-augmented technologies, and to learn from their experience and expertise to enhance our forthcoming innovation. Securing this collaboration with Bayer, which was catalyzed by our participation in the G4A program, is a testament to Cyclica’s value proposition.”


About Cyclica:

Cyclica is a Toronto-based biotechnology company that is driving drug discovery by empowering scientists in pharma with an integrated cloud-based and AI-augmented platform that enhances how they design, screen and personalize medicines. To learn more, visit www.cyclicarx.com.


Contacts

Media Inquires:
Naheed Kurji
President and CEO
Cyclica Inc
naheed.kurji@cyclicarx.com

   
Record changed: 2018-12-11

Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px

More documents for Bayer (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px




» top